Markets
markets

Rocket Lab builds on Friday’s gain after landmark $816 million satellite contract and record Electron rocket launches in 2025

Rocket Lab is ending the year with a timely boost to its fortunes.

The company is up another ~4% in premarket trading on Monday, building on Friday’s ~18% gain, which came after the company announced an $816 million deal to design and manufacture 18 satellites for the US Space Development Agency on Friday, marking the company’s largest single contract to date.

Per Rocket Lab’s press release, CEO Peter Beck commented that “as the only commercial provider producing both spacecraft and payloads in-house for the SDA Tracking Layer, Rocket Lab is delivering a truly disruptive solution that combines speed, resilience, and affordability,” emphasizing the company’s vertically integrated manufacturing approach, with all of the major components of its satellites designed and produced in-house.

In a separate announcement on Monday, Rocket Lab also shared the successful launch of its 21st Electron rocket of the year and the seventh for Japanese Earth imaging company Institute for Q-shu Pioneers of Space, Inc., finishing the year with 100% mission success for its flagship spacecraft and establishing it as the world’s most frequently launched small-lift orbital rocket, according to the company. The company has plans for five additional Electron launches for iQPS in 2026.

Another name in the space arena, satellite peer AST SpaceMobile, is also trading higher after spiking at the end of last week. Following a 15% gain on Friday, ASTS is up another 4% early on Monday as optimism builds for its BlueBird 6 launch, pivotal to the company’s direct-to-smartphone strategy, scheduled to launch on December 23, 2025, at 10:24 p.m. ET.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets
Luke Kawa

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.